We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+6.4%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$211M
AUM Growth
-$31.9M
Cap. Flow
-$34.9M
Cap. Flow %
-16.5%
Top 10 Hldgs %
55.13%
Holding
62
New
14
Increased
11
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$15.7M
2
MRK icon
Merck
MRK
+$6.7M
3
GILD icon
Gilead Sciences
GILD
+$4.79M
4
EXEL icon
Exelixis
EXEL
+$3.91M
5
INMD icon
InMode
INMD
+$3.81M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$10.3M
2
HUM icon
Humana
HUM
+$9.28M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.95M
4
STRM
Streamline Health Solutions
STRM
+$7.35M
5
CALY
Callaway Golf Company
CALY
+$5.49M

Sector Composition

Rank Sector Weight
1 Healthcare 90.32%
2 Consumer Staples 3.22%
3 Technology 0.69%
4 Consumer Discretionary 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
1
Cigna
CI
$76.6B
$18M 8.5%
75,000
+67,000
+838% +$15.7M
PCRX icon
2
Pacira BioSciences
PCRX
$1.02B
$15.6M 7.4%
205,000
-35,000
-15% -$2.33M
LNTH icon
3
Lantheus
LNTH
$6.82B
$13.8M 6.54%
250,000
-105,000
-30% -$3.94M
MRK icon
4
Merck
MRK
$324B
$12.7M 6.02%
155,000
+85,000
+121% +$6.7M
BVS icon
5
Bioventus
BVS
$799M
$11.6M 5.5%
825,001
-49,999
-6% -$669K
SIBN icon
6
SI-BONE Inc
SIBN
$737M
$10.7M 5.08%
475,000
-75,000
-14% -$1.56M
RIGL icon
7
Rigel Pharmaceuticals
RIGL
$680M
$9.72M 4.6%
325,000
-125,000
-28% -$3.38M
CERS icon
8
Cerus
CERS
$587M
$9.06M 4.29%
1,650,000
+650,000
+65% +$3.6M
MDT icon
9
Medtronic
MDT
$107B
$8.32M 3.94%
75,000
-50,000
-40% -$5.28M
ANGO icon
10
AngioDynamics
ANGO
$562M
$6.89M 3.26%
320,000
-25,000
-7% -$567K
TPB icon
11
Turning Point Brands
TPB
$1.47B
$6.8M 3.22%
200,000
-50,000
-20% -$1.7M
THC icon
12
Tenet Healthcare
THC
$20.1B
$6.45M 3.05%
75,000
-125,000
-63% -$10.3M
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.23M 2.95%
370,000
+145,000
+64% +$2.14M
CVS icon
14
CVS Health
CVS
$137B
$5.06M 2.39%
50,000
+10,000
+25% +$1.05M
INMD icon
15
InMode
INMD
$872M
$4.8M 2.27%
130,000
+85,000
+189% +$3.81M
JAZZ icon
16
Jazz Pharmaceuticals
JAZZ
$15.9B
$4.67M 2.21%
30,000
+5,000
+20% +$726K
PHR icon
17
Phreesia
PHR
$632M
$4.61M 2.18%
175,000
+100,000
+133% +$3.06M
EXEL icon
18
Exelixis
EXEL
$13.9B
$4.53M 2.15%
+200,000
New +$3.91M
MDRX
19
DELISTED
Veradigm Inc. Common Stock
MDRX
$4.5M 2.13%
200,000
– –
GILD icon
20
Gilead Sciences
GILD
$161B
$4.46M 2.11%
+75,000
New +$4.79M
HSIC icon
21
Henry Schein
HSIC
$9.74B
$4.36M 2.06%
50,000
+13,000
+35% +$1.06M
ATRC icon
22
AtriCure
ATRC
$1.77B
$4.27M 2.02%
65,000
-35,000
-35% -$2.27M
TCMD icon
23
Tactile Systems Technology
TCMD
$620M
$2.48M 1.17%
+122,756
New +$2.15M
VTRS icon
24
Viatris
VTRS
$20.1B
$2.45M 1.16%
225,000
-275,000
-55% -$3.62M
VRAY
25
DELISTED
ViewRay, Inc.
VRAY
$2.35M 1.11%
600,000
-600,000
-50% -$2.55M
1
2 3

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q1 2022 Portfolio in Review

As of Q1 2022, Tamarack Advisers held 62 positions worth $211M, down 13% from $243M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Tamarack Advisers withdrew a net $34.9M in Q1 2022, closing 16 positions and reducing 20 holdings. Its most notable exit was Humana, an estimated $9.28M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 84% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Tamarack Advisers opened a new position in Gilead Sciences worth $4.46M.

  • Tamarack Advisers's largest Q1 2022 buy was Gilead Sciences: 75,000 shares worth $4.46M.
  • Tamarack Advisers added most to Cigna in Q1 2022, an estimated $15.7M increase.
  • Tamarack Advisers's biggest Q1 2022 reduction was Tenet Healthcare, cutting an estimated $10.3M.
  • Tamarack Advisers fully exited Humana in Q1 2022, selling an estimated $9.28M.
  • Tamarack Advisers's ten largest holdings make up 55% of its $211M portfolio in Q1 2022.
  • Tamarack Advisers opened 14 new positions and closed 16 in Q1 2022.
  • Tamarack Advisers's portfolio value fell 13% quarter-over-quarter to $211M.

Based on Tamarack Advisers's 13F filing for Q1 2022, filed 11 May 2022.